Renalytix (STU:2O90) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2O90 Renalytix PLC STU:2O90
12 GF Score
Price €2.70
GF Value €5.09
! 3 Warning Signs
View Full Analysis

What is Renalytix FFO per Share?

FFO per Share only applies to REITs.

STU:2O90
12GF Score
Renalytix PLC STU:2O90
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Renalytix (STU:2O90) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of €2.70 is trading 47% below its estimated GF Value™ of €5.09.

Key valuation signals for STU:2O90:

  • FFO per Share:
  • GF Value™: €5.09 vs. price of €2.70 (47% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the STU:2O90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
12GF Score

Get the complete analysis for STU:2O90

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.70
Price
€5.09
GF Value